



DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St W
Toronto ON M5X 1E2
www.dlapiper.com

DLA Piper (Canada) LLP

VIA SEDAR

Alberta Securities Commission
British Columbia Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Ontario Securities Commission
Office of the Yukon Superintendent of Securities

May 20, 2021

Re: Nurosene Health Inc. – Final Long Form Prospectus dated May 20, 2021 filed pursuant to National Instrument 41-101 *General Prospectus Requirements* and Multilateral Instrument 11-102 *Passport System*

We refer to the final long form prospectus (the “**Prospectus**”) of Nurosene Health Inc. (the “**Corporation**”) dated May 20, 2021, relating to the distribution of common shares of the Corporation.

We consent to the use of our name, DLA Piper (Canada) LLP, on the cover page and under the heading "Experts" in the Prospectus and to the use of our name, DLA Piper (Canada) LLP, and our opinions under the heading "Eligibility for Investment" in the Prospectus.

We confirm that we have read the Prospectus and that we have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are derived from our opinions in the Prospectus or that are within our knowledge as a result of the services we performed in connection with such opinions.

Sincerely,

(signed) "DLA Piper (Canada) LLP"